Andrew P. Han

In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.

Activist investor Carl Icahn sent a letter to Illumina shareholders outlining plans to take control of three board seats with the goal of promptly divesting Grail.

New, more accurate methods are posing problems for the NGS ecosystem as researchers rethink the concept of accuracy altogether.

The Hong Kong-based plaintiffs alleged that PacBio has copied their method of calling methylated bases using quirks of the PacBio sequencing method.

An improved sample prep workflow for single-cell methylation analysis offers the prospect of commercialization, which could be readily taken up in cancer genomics.

The firm has improved upon the whole-transcriptome spatial genomics method developed by the Broad Institute's Fei Chen and Evan Macosko.

The firm expects 2023 revenues to range between $165 million and $180 million, representing 29 percent to 40 percent growth over 2022.

The Pleasanton, California-based firm posted revenues of $156.2 million for Q4, beating the consensus Wall Street estimate of $148.7 million.

Single-cell transcriptome sequencing and spatial omics technologies have helped pave the way for a traditionally genetics-focused crowd to pursue proteins.

At last week's meeting, the firms shared their respective work on developing assays to detect 6,000 RNAs on the CosMx platform and 5,000 RNAs on the Xenium instrument.